Document is current
Any future updates will be listed below
-
Authors
Schwab, Johan
Foglierini, Mathilde https://orcid.org/0000-0001-7538-4262
Pescosolido, Eva
Pacheco, Ines https://orcid.org/0009-0005-4720-9658
Ruiz Buendía, Gustavo A. https://orcid.org/0000-0002-4935-1480
Madelon, Natacha
Pellaton, Celine
Banderet, Véronique
Ribi, Camillo
Bergmann, Marcel M.
Didierlaurent, Arnaud M. https://orcid.org/0000-0002-4736-9003
Fenwick, Craig https://orcid.org/0000-0002-9435-0110
Duperrex, Olivier https://orcid.org/0000-0002-0932-6846
Muller, Yannick D. https://orcid.org/0000-0003-0513-7156
-
Funding
Funding for this research was provided by:
Giorgi-Cavaglieri Foundation
- License Information
-
More Information
Article History
Received: 16 March 2024
Accepted: 24 October 2024
First Online: 30 November 2024
Competing interests
: The authors declare the following competing interests: Dr Fenwick report having a patent pending (application No. EP20205298.1) for a SARS-Cov2 neutralization assay. Prof. Muller has received grant support/consulting income from AstraZeneca, Viatris, Blueprint Medicine, Sanofi and GSK. Prof. Didierlaurent received research grants from Moderna, GSK and Sanofi outside the scope of this study. The research was conducted without any other commercial or financial relationships that could be construed as a potential conflict of interest to this study. Authors J. Schwab, M. Foglierini, E. Pescosolido, I. Pacheco, G. A. Ruiz Buendía, N. Madelon, C. Pellaton, V. Banderet, C. Ribi, M. M. Bergmann, and O. Duperrex declare no competing interests relevant to this study.
